RUNX3 and gastric cancer: Although circulating methylated RUNX3 measured by the conventional bisulfite-based serum methylation assay in the blood in patients with gastric cancer was reported by other investigators [8,9,23,24], the sensitivity for stage I gastric cancer, including early gastric cancer, is extremely low, ranging from 0.0% to 19.0% [9,24].